Advanced Biomed Inc. Files S-1/A Amendment

TL;DR

Advanced Biomed Inc. just filed an S-1/A amendment, looks like they're still pushing for that IPO.

AI Summary

Advanced Biomed Inc. filed an S-1/A amendment on February 7, 2025, for its registration statement. The company, incorporated in Nevada, has its principal executive offices located at 401 Ryland St, Reno, NV 89502, with a business phone number of 86-21-20510823. This filing is an amendment to a previous registration statement filed under the Securities Act of 1933.

Why It Matters

This S-1/A filing indicates Advanced Biomed Inc. is moving forward with its public offering process, which could lead to increased liquidity and capital for the company.

Risk Assessment

Risk Level: medium — S-1/A filings are typically associated with initial public offerings or significant corporate changes, which inherently carry market and execution risks.

Key Numbers

• 333-272110 — Registration Number (Identifies this specific SEC registration filing.)
• 8071 — SIC Code (Classifies the company's industry as Medical Laboratories.)

Key Players & Entities

• Advanced Biomed Inc. (company) — Registrant
• February 7, 2025 (date) — Filing Date
• 333-272110 (registration_number) — SEC Registration Number
• 8071 (sic_code) — Standard Industrial Classification Code
• NV (state) — State of Incorporation
• 401 RYLAND ST STE 200-A RENO, NV 89502 (address) — Principal Executive Offices
• 86-21-20510823 (phone_number) — Business Phone
• Cogency Global Inc. (company) — Agent for Service
• Fang Liu (person) — Legal Counsel
• VCL Law LLP (company) — Legal Firm

FAQ

Key Financial Figures

• $0.001 — 5,000 shares of common stock, par value $0.001 per share (“Common Stock”),
• $4.00 — Primary Offering price will be between $4.00 to $6.00 per share of Common Stock. Pri
• $6.00 — Offering price will be between $4.00 to $6.00 per share of Common Stock. Prior to thi

Filing Documents

• vc062_s1a.htm (S-1/A) — 2105KB
• vc062_img01.jpg (GRAPHIC) — 9KB
• vc062_img02.jpg (GRAPHIC) — 32KB
• vc062_img03.jpg (GRAPHIC) — 22KB
• vc062_img04.jpg (GRAPHIC) — 57KB
• vc062_img05.jpg (GRAPHIC) — 85KB
• vc062_img06.jpg (GRAPHIC) — 9KB
• vc062_img07.jpg (GRAPHIC) — 111KB
• vc062_img08.jpg (GRAPHIC) — 67KB
• vc062_img09.jpg (GRAPHIC) — 109KB
• vc062_img10.jpg (GRAPHIC) — 67KB
• vc062_img11.jpg (GRAPHIC) — 57KB
• vc062_img12.jpg (GRAPHIC) — 53KB
• vc062_img13.jpg (GRAPHIC) — 69KB
• vc062_img14.jpg (GRAPHIC) — 26KB
• vc062_img15.jpg (GRAPHIC) — 43KB
• vc062_img16.jpg (GRAPHIC) — 23KB
• vc062_img17.jpg (GRAPHIC) — 10KB
• vc062_img18.jpg (GRAPHIC) — 23KB
• 0001575872-25-000138.txt ( ) — 3309KB

From the Filing

As filed with the United States Securities and Exchange Commission on February 7, 2025. Registration No. 333-272110 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 AMENDMENT NO. 16 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Advanced Biomed Inc. (Exact name of registrant as specified in its charter) Nevada 8071 87-2177170 (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Number) (I.R.S. Employer Identification Number) No. 689-85 Xiaodong Road, Yongkang District Tainan City, Taiwan Tel: 886-6-3121716 (Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices) Cogency Global Inc. 122 East 42nd Street, 18th Floor New York, NY 10168 (212) 947-7200 (Name, address, including zip code, and telephone number, including area code, of agent for service) Copies of all communications to: Fang Liu, Esq. VCL Law LLP William S. Rosenstadt, Esq. Mengyi “Jason” Ye, Esq. 1945 Old Gallows Road Ortoli Rosenstadt LLP Suite 260 366 Madison Avenue, 3rd Floor Vienna, VA 22182 New York, NY 10017 Telephone: (703) 919-7285 Telephone: (212) 588-0022 Approximate date of commencement of proposed sale to the public: As soon as practicable after the effective date of this registration statement. If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, check the following box: If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, check the following box and list the Securities Act registration If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. If this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. Large Accelerated Filer Accelerated Filer Non-Accelerated Filer Smaller Reporting Company Emerging Growth Company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. The registrant hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until the registrant shall file a further amendment which specifically states that this registration statement shall hereafter become effective in accordance with Section 8(a) of the Securities Act of 1933 or until the registration statement shall become effective on such date as the United States Securities and Exchange Commission, acting pursuant to said Section 8(a), may determine. EXPLANATORY NOTE This Registration Statement contains two prospectuses, as set forth below. Primary Offering Prospectus. A prospectus to be used for the initial primary underwritten public offering of 1,875,000 Common Stock of the Registrant through the underwriter named on the cover page of the Primary Offering Prospectus. The initial primary underwritten public offering is referred to as the “Primary Offering.” Resale Prospectus. A prospectus to be used for the resale by the selling stockholders of up to 1,875,000 Common Stock of the Registrant (the “Resale Shares” and each a “Resale Share”). Each of the two selling stockholders identified in the Resale Prospectus is referred to as a “Selling Stockholder” and together, “Selling Stockholders.” The offering of the Resale Shares is referred to as the “Resale Offering.” The Resale Prospectus is substantively identical to the Primary Offering Prospectus, except for the following principal points: they contain different outside and inside front covers and back covers; the Offering section in the Prospectus Summary section from the Primary Offering Prospectus on page 12 is deleted and replaced with a revised the Offering section on page Alt-1; the Use of Proceeds section from the Primary Offering Prospectus on page 47 is deleted and replaced with a revised the Use of Proceeds sect

View Full Filing

View this S-1/A filing on SEC EDGAR